1-8 of 8
Shoko Furukawa
Close
Sort by
Journal Articles

Impact of Anticoagulant Function By the Addition of Heparinoid in Vitro in the Plasmas from Patients with Hemophilia and Von Willebrand Disease

Masahiro Takeyama, Tomoya Miyatake, Shoko Furukawa, Kenichi Ogiwara, Keiji Nogami
Journal: Blood
Blood (2023) 142 (Supplement 1): 5469.
https://doi.org/10.1182/blood-2023-174793
Published: 2023
Journal Articles

Contribution of the Residues 488-490 on the Factor (F)VIII A2 Domain and the Residue 2239 on the FVIII C2 Domain for the Interaction between FVIII and Protein S

Shoko Furukawa, Masahiro Takeyama, Keiji Nogami
Journal: Blood
Blood (2023) 142 (Supplement 1): 2603.
https://doi.org/10.1182/blood-2023-174626
Published: 2023
Journal Articles

Escaping Ability of Human-Porcine Hybrid Factor VIII from Anti-Factor VIII Inhibitors with an A2 or C2 Epitope

Kuniyoshi Mizumachi, Yuto Nakajima, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami
Journal: Blood
Blood (2022) 140 (Supplement 1): 8430–8431.
https://doi.org/10.1182/blood-2022-165714
Published: 2022
Journal Articles

Global Coagulation Potentials and Breakthrough Bleeds in Emicizumab-Treated Hemophilia a Patients Were Similar to Mild Hemophilia a Patients

Yuto Nakajima, Kuniyoshi Mizumachi, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami
Journal: Blood
Blood (2021) 138 (Supplement 1): 2100.
https://doi.org/10.1182/blood-2021-146337
Published: 2021
Journal Articles

Effects of Bypassing Hemostatic Agents in the Co-Presence of NXT007, Emicizumab-Based Engineered Bispecific Antibody to Fixa/Fx, Using in Vitro Global Assays: Rough Indicators for Their Concomitant Use

Kenichi Ogiwara, Shoko Furukawa, Kana Sasai, Keito Inaba, Takehisa Kitazawa, Keiji Nogami
Journal: Blood
Blood (2021) 138 (Supplement 1): 2114.
https://doi.org/10.1182/blood-2021-149412
Published: 2021
Journal Articles

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

Shoko Furukawa, MD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Ryu Kasai, MSc, Midori Shima, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3793.
https://doi.org/10.1182/blood-2018-99-114355
Published: 2018
Journal Articles

Identification of a Factor X-Interactive Site on the Factor VIII A2 Domain

Masahiro Takeyama, MD PhD, Keiji Nogami, MD PhD, Shoko Furukawa, MD, Midori Shima, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3760.
https://doi.org/10.1182/blood.V128.22.3760.3760
Published: 2016
Journal Articles

Total-Thrombus-Formation Analysis System Using a Microchip Flow Chamber Reflects Bleeding Severity of Patients with Type 1 Von Willebrand Disease.

Kenichi Ogiwara, MD, PhD, Keiji Nogami, MD, PhD, Tomoko Matsumoto, PhD, Shoko Furukawa, MD, Hiroaki Minami, MD, Kazuya Hosokawa, PhD, Midori Shima, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2237.
https://doi.org/10.1182/blood.V120.21.2237.2237
Published: 2012